-
Home
-
Media and Information
- Press Releases
Press Releases
- Details
April 14, 2015–The Plasma Protein Therapeutics Association recognizes World Hemophilia Day, an annual international event sponsored by the World Federation for Hemophilia that seeks to raise awareness of people living with inherited bleeding disorders.
- Details
The Plasma Protein Therapeutics Association joins more than 300 organizations in 56 countries in recognizing the 8th annual International Rare Disease Day on February 28.
Sponsored by the National Organization of Rare Disorders and Rare Diseases Europe, Rare Diseases Day seeks to raise awareness among the general public and policymakers about rare diseases, impacting lives all over the globe.
- Details
Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) recently launched the Cross Donation Check System (CDCS), a new electronic database designed to assist plasma centers in checking donors more efficiently and effectively.
- Details
(20th January 2015 – Brussels) – AESGP, EFPIA, EGA, and PPTA are pleased to announce today’s release of the joint principles for “Communication of information on quality and manufacturing potential supply disruption”. This document forms part of the industry response to the EMA (European Medicines Agency) call for voluntary and proactive action, to provide European patients with continuous access to medicines.
- Details
Annapolis, MD--The second annual International Plasma Awareness Week (IPAW) will be celebrated October 12-18. A joint initiative of the Plasma Protein Therapeutics Association (PPTA) and its member companies, IPAW is designed to:
- Details
April 17, 2014–The Plasma Protein Therapeutics Association (PPTA) recognizes World Hemophilia Day, an annual international event sponsored by the World Federation for Hemophilia (WFH) that seeks to raise awareness of people living with inherited bleeding disorders.
- Details
ANNAPOLIS, MD—The Plasma Protein Therapeutics Association (PPTA) has awarded Plazmaferezis Állomás Kft (PFÁ), a member operating within the Kedrion group of companies, with International Quality Plasma Program (IQPP) certification for its plasma collection centers in Hungary; two in Budapest and one in Debrecen. The three centers are the first in the country to become IQPP certified.
- Details
Dear PPTA Stakeholders:
I would like to provide a status report on implementation of PPTA’s European Data Program.
As you know, PPTA launched the program in November 2013 starting with the reporting of Recombinant Factor VIII data. We committed as well to soon begin reporting data on a more complete set of plasma protein therapies. Today we are able to honor that commitment. Please click here to access the data.
- Details
Dear PPTA Stakeholders:
PPTA is pleased to announce the addition of public reporting of monthly distribution data for plasma protein therapies to its Web site, www.pptaglobal.org.1 This data is intended to provide patients and other stakeholders, as well as manufacturers and regulators, with information regarding the availability of these critical, often life-sustaining, therapies.
- Details
Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) and its member companies, the major collectors of human plasma and manufacturers of plasma protein therapies will hold their annual PPTA Business Forum in Denver on October 13. The meeting coincides with a kickoff celebration for International Plasma Awareness Week (IPAW), October 13-20, a new global awareness event designed to:
Media and Information
PPTA News
-
PPTA Highlights Importance of Patient Access to Plasma Protein Therapies +
On July 16, the Plasma Protein Therapeutics Association (PPTA) submitted comments following the Trump administration’s “American Patients First” drug policy blueprint. In any discussions impacting the ability of individuals living with rare, chronic, and life-threatening diseases, PPTA remains steadfast to its mission to promote the availability of and access to safe and effective plasma protein therapies for all patients in the world.
Read More -
Statement on Romanian Competition Council +
To our big surprise representatives from the Romanian Competition Authority arrived at our offices in Brussels on June 26 and were joined by Belgian police and the Belgian Competition Authority. The investigators were interested to know whether there was a coordinated effort to restrict supply of immunoglobulin therapies to the Romanian market for the purposes of pressuring the government to exempt these therapies from the “claw back” tax. PPTA cooperated fully with the investigators.
Read More -
Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA) +
The pharmaceutical industry represented by AESGP1, EFPIA2, EUCOPE3, EuropaBio4, Medicines for Europe and PPTA5 – henceforth referred to as ‘the pharmaceutical industry’ – generally welcomes the European Commission (EC)’s Proposal for a Regulation on HTA6. We understand the scope of the joint clinical assessments foreseen in the proposal is limited to medicinal products subject to the centralised marketing authorisation, and exempting generic, biosimilar and non-prescription medicines7.
Read More
- 1
- 2
- 3
The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.
Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.